Regentis Biomaterials Ltd. (NYSE American: RGNT), a regenerative medicine company focused on innovative tissue repair solutions, announced that CEO and Executive Chairman Ehud Geller will present at the 2026 ThinkEquity Conference on Oct. 15, 2026, at 10 a.m. at the Mandarin Oriental Hotel in New York City. Geller will provide an overview of the company’s GelrinC® technology, recent clinical developments, progress in its ongoing U.S. Food and Drug Administration (FDA) pivotal Phase III trial and preparations for commercialization in Europe, where GelrinC has received CE Mark approval. Geller and Chief Financial Officer Ori Gon will also be available for one-on-one meetings with investors.
The presentation comes at a critical time for Regentis as it advances its lead product, GelrinC, a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing the surrounding cells to regenerate cartilage in a controlled and synchronous process. GelrinC aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S. where no off-the-shelf treatment is available. The company’s Gelrin platform technology, based on synchronized, degradable hydrogel implants, regenerates damaged or diseased tissue including inflamed cartilage and bone.
For investors, the ThinkEquity Conference offers a direct opportunity to gauge Regentis’ progress on its FDA pivotal Phase III trial and its European commercialization strategy. Successful trial outcomes and a smooth European launch could position the company to capture a significant share of the cartilage repair market. The CE Mark approval in Europe provides a regulatory headstart, while the U.S. trial remains a key value driver. The company’s participation in the conference underscores its commitment to engaging with the investment community as it approaches potential commercialization milestones.
The announcement was disseminated through MissionIR, a specialized communications platform that assists IR firms with syndicated content to enhance the visibility of private and public companies. MissionIR is one of 75+ brands within the Dynamic Brand Portfolio @ IBN, which provides access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution and a full array of tailored corporate communications solutions. For more information, visit MissionIR.
The latest news and updates relating to RGNT are available in the company’s newsroom at https//ibn.fm/RGNT. To view the full press release, visit https://ibn.fm/wicmT. Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer.
